{"id":"NCT00764946","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)","officialTitle":"A Phase III Open-Label Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of MK0518/Raltegravir in a Diverse Cohort of HIV-Infected Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2008-10-02","resultsPosted":"2012-04-12","lastUpdate":"2017-03-21"},"enrollment":209,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus"],"interventions":[{"type":"DRUG","name":"Comparator: raltegravir","otherNames":["ISENTRESS"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female, either having received antiretroviral drugs before or not.","primaryOutcome":{"measure":"Number of Participants Who Achieved HIV Ribonucleic Acid (RNA) <50 Copies/mL at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"Treatment Experienced - Failing Current Therapy","deltaMin":44,"sd":null},{"arm":"Treatment Experienced - Treatment Intolerant","deltaMin":43,"sd":null},{"arm":"Treatment Naive","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23351187"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":97},"commonTop":["Nausea","Upper respiratory tract infection","Diarrhoea","Vomiting","Oral candidiasis"]}}